

Navana Pharmaceuticals Limited

Interim Financial Statements (Un-audited)

For the Period from 01 July 2022 -31 March 2023

Navana Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at 31 March 2023

(Amount in BDT)

Particulars	Notes	As at	
		31-Mar-2023	30-Jun-2022
Assets			
Non-Current Assets:			
Property, Plant and Equipment	3.00	3,690,263,305	3,421,837,366
Intangible Asset	3.01	605,000	770,000
Capital Work in Progress	4.00	301,563,627	403,007,534
Right-of-Use Asset	5.00	202,467,621	204,018,990
Investment in Marketable Securities (Fair Value)	6.00	179,054,985	159,028,097
Total Non-Current Assets		4,373,954,538	4,188,661,986
Current Assets:			
Inventories	7.00	1,067,785,410	1,009,145,823
Trade and Other Receivables	8.00	764,026,328	547,819,881
Advances, Deposits and Prepayments	9.00	1,936,317,143	1,168,436,458
Goods In Transit	10.00	279,825,101	103,608,600
Cash and Cash Equivalents	11.00	471,249,364	66,427,585
Total Current Assets		4,519,203,347	2,895,438,346
Total Assets		8,893,157,885	7,084,100,333
Equity And Liabilities			
Equity:			
Paid-up Share Capital	12.00	1,074,162,170	802,301,500
Share Premium	13.00	448,170,105	-
Revaluation Reserve	14.00	1,966,271,633	1,966,271,633
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/ (Loss) Reserve	6.00	(35,365,847)	(95,356,927)
Retained Earnings		334,625,462	204,242,971
Total Equity:		4,393,453,671	3,483,049,324
Liabilities			
Non-Current Liabilities:			
Loan from Directors	15.00	30,000,000	30,000,000
Lease Liabilities	16.02	89,600,269	100,720,006
Long Term Loan	17.02	71,405,249	141,390,720
Deferred Tax Liability	18.00	49,147,287	42,362,502
Total Non-Current Liabilities		240,152,805	314,473,228
Current Liabilities:			
Short Term Loan	19.00	3,617,980,054	2,682,055,890
Lease Liabilities (Current Maturity)	16.01	28,204,042	29,254,646
Long Term Loan (Current Maturity)	17.01	5,645,498	28,125,222
Trade and Other Payables	20.00	601,255,524	547,142,023
Unclaim Dividend Payable		6,466,292	-
Total Current Liabilities		4,259,551,410	3,286,577,781
Total Liabilities		4,499,704,214	3,601,051,009
Total Equity and Liabilities		8,893,157,885	7,084,100,333
Net Asset Value (NAV) Per Share	30.00	40.90	43.41

Annexed notes are integral part of these financial statement.


Chief Financial Officer


Company Secretary


Managing Director


Director


Director

Navana Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the period from 01 July 2022 to 31 March 2023

Particulars	Notes	Interim Period		Third Quarter	
		July 2022- March 2023	July 2021- March 2022	Jan-March 2023	Jan-March 2022
		(Amount in BDT)			
Net Sales	21.00	4,234,623,905	3,662,290,916	1,502,638,178	1,224,832,851
Less: Cost of Good Sold	22.00	2,338,429,481	2,041,751,687	862,936,389	685,121,122
Gross Profit		1,896,194,424	1,620,539,229	639,701,789	539,711,729
Less: Operating Expenses					
Administrative Expenses	23.00	149,936,588	123,804,419	49,149,653	41,419,456
Selling & Marketing Expenses	24.00	900,116,347	922,520,783	283,466,354	307,655,556
Distribution Expenses	25.00	280,255,931	226,439,985	91,669,803	77,492,795
Total Operating Expenses:		1,330,308,866	1,272,765,187	424,285,809	426,567,807
Operating Profit		565,885,558	347,774,042	215,415,980	113,143,922
Less: Finance Expenses	26.00	217,784,884	145,489,183	75,177,655	50,436,250
Add: Other Income/(loss)	27.00	(30,371,524)	107,707,111	(15,329,831)	37,577,814
Profit before WPPF & Tax		317,729,149	309,991,969	124,908,494	100,285,486
Contribution to WPPF		15,129,959	14,761,522	5,948,024	4,953,311
Profit before tax		302,599,190	295,230,446	118,960,471	95,332,175
Less: Income Tax		54,058,860	103,391,915	13,977,064	27,329,109
Current Tax	28.00	47,274,075	103,769,479	11,757,079	27,457,900
Deferred Tax Expense/(Income)		6,784,784	(377,564)	2,219,984	(128,791)
Profit after Tax		248,540,330	191,838,531	104,983,406	68,003,066
Other Comprehensive Income					
Unrealized Gain/(loss) on Marketable Security		59,991,080	(4,079,282)	40,824,042	(4,079,282)
Total Comprehensive Income		308,531,410	187,759,248	145,807,448	63,923,784
Earnings Per Share (EPS)	29.00	2.57	2.39	1.09	0.85

Annexed notes are integral part of these financial statement.


Chief Financial Officer


Company Secretary


Managing Director


Director


Director

Navana Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the period from 01 July 2022 to 31 March 2023

As at 31 March 2023

Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2022	802,301,500	-	-	1,966,271,633	605,590,148	(95,356,927)	204,242,971	3,483,049,324
Profit after Tax	-	-	-	-	-	-	248,540,330	248,540,330
Received from IPO Share Subscription	-	-	750,000,018	-	-	-	-	750,000,018
Allotment of Shares for IPO	271,860,670	478,139,348	(750,000,018)	-	-	-	-	-
11% Cash Dividend for YE 30 June 2022	-	-	-	-	-	-	(118,157,839)	(118,157,839)
Less: Adj of IPO Expense	-	(29,969,243)	-	-	-	-	-	(29,969,243)
Adj. to Unrealized Gain/(Loss) on FVOCI	-	448,170,105	-	1,966,271,633	605,590,148	(35,365,847)	-	59,991,080
	1,074,162,170	448,170,105	-	1,966,271,633	605,590,148	(35,365,847)	334,625,462	4,393,453,671

As at 30 June 2022


Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2021	802,301,500	-	-	1,966,271,633	-	-	535,831,580	3,304,404,713
Profit after Tax during the period	-	-	-	-	-	-	274,001,539	274,001,539
Transfer to Capital Reserve	-	-	-	-	605,590,148	-	(605,590,148)	-
Unrealized Gain/(Loss) on Marketable Securities	-	-	-	-	-	(95,356,927)	-	(95,356,927)
	802,301,500	-	-	1,966,271,633	605,590,148	(95,356,927)	204,242,971	3,483,049,324


Chief Financial Officer


Company Secretary


Managing Director


Director


Director